It was previously reported that anti-GSK3β treatments in other cancer types, including pancreatic cancer and glioblastoma, sensitize the cells to chemotherapeutic reagents and ionizing radiation [37–40]. This evidence concerns the gene GSK3B and familial pancreatic carcinoma.